Merck says "media hype" overlooks Vytorin value
96084
The chief executive of Merck & Co on  Wednesday said negative media coverage of a clinical trial of  the company's blockbuster Vytorin cholesterol drug has unfairly  overlooked benefits of the medicine.
434277
The market might overlook the drug maker's promising programs.
114249
The cholesterol drug Vytorin is now getting attention that is anything but funny.
652619
Bad press from Vioxx shouldn't overshadow the company's new offering.
216989
Merck &amp; Co Inc. is evaluating why its withdrawn painkiller Vioxx raises the chance of heart attack and stroke, but it has not found a mechanism of action, a company official said on Monday.
218529
Shares of drugmaker Merck &amp; Co. Inc. (MRK.N: Quote, Profile, Research) traded 1.52 percent higher on volume of more than 61,000 shares in pre-market dealings on Friday, a day after
55690
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's  and Schering-Plough Corp's  popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.
732193
* The world&#39;s biggest drug company loses $25 billion in market value in one day as investors fear another Vioxx debacle. NEW YORK - Pfizer Inc.
83518
Merck & Co and Schering-Plough Corp said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
473365
Merck & Co. Inc.  shares could  rise to $70 by 2010 if the drugmaker continues to deliver on  its promise of double-digit earnings growth, Barron's said in  its October 29 edition.
575614
Merck and Schering report bad news, but how much will it affect sales?
32044
High doses of Zocor provide no benefits in preventing new problems in heart attack patients: study. MUNICH  - Merck&#39;s anti-cholesterol drug Zocor suffered a setback after a major study found high
467982
&#151; Merck & Co., the US drug maker that recalled its Vioxx painkiller because of a link to heart disease, said short-term studies show the company's planned successor pill, Arcoxia, is safer.
128103
Considering the debacle with the flu vaccine, Chiron&#39;s (Nasdaq: CHIR) earnings release announcing that it beat analyst expectations is more than somewhat superfluous.
196912
Nonbinding offers for the generics  business of Merck KGaA , worth at least 4 billion  euros ($5.3 billion), are due on Monday, a source close to the  sale process told Reuters, confirming a newspaper report.
455038
U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol drug Vytorin after a study showed it was no better than a generic in preventing the build-up of fatty plaque.
226044
U.S. health officials said on Friday  they would review whether to take regulatory action over Merck  & Co Inc  and Schering-Plough's  cholesterol  medicine Vytorin following the drug's failure to work better  than a generic drug in a study of plaque build-up in neck  arteries.